Related Experiment Video
Updated: Jan 26, 2026
08:34
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
1.2K
[Ulcerative colitis: Does the modulation of gut microbiota induce long-lasting remission?]
Andreas Stallmach1, Philip Grunert1, Dietmar Pieper2
1Klinik für Innere Medizin IV (Gastroenterologie, Hepatologie, Infektiologie, Interdisziplinäre Endoskopie), Universitätsklinikum Jena, Germany.
Zeitschrift Fur Gastroenterologie
|April 16, 2019
Summary
Fecal microbiota transplantation (FMT) shows promise for ulcerative colitis (UC) by restoring gut microbial balance. However, more research is needed to confirm its long-term efficacy and safety in UC patients.
Area of Science:
- Gastroenterology
- Microbiology
- Immunology
Background:
- Ulcerative colitis (UC) pathogenesis involves gut microbiota alterations, immune dysregulation, and genetic factors.
- The precise role of gut microbiota changes in UC inflammation (cause or effect) remains unclear.
- Fecal microbiota transplantation (FMT) is explored as a strategy to restore gut microbial homeostasis.
Purpose of the Study:
- To review current efficacy and safety data of FMT for UC.
- To discuss potential challenges and future research directions for FMT in UC treatment.
Main Methods:
- Review of recent case series and randomized controlled trials on FMT for UC.
- Evaluation of safety and efficacy data from clinical studies.
Main Results:
- FMT is an established treatment for recurrent Clostridioides difficile infection.
- Preliminary data suggest FMT may restore microbial diversity and homeostasis in UC.
- Long-term outcomes and safety data for FMT in UC require further investigation.
Conclusions:
- FMT presents a promising therapeutic option for UC.
- Current evidence supports FMT's use in clinical trials for UC, focusing on long-term outcomes and safety.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
953
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
953
01:29Drugs for Treatment of Ulcerative Colitis in IBD
483
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
483
01:28Peptic Ulcer Disease II: Pathophysiology
2.0K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.0K
01:30Peptic Ulcer Disease I: Introduction
770
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
770
01:26Peptic Ulcer Disease IV: Management
465
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
465
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
1.2K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K